Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Suma Krishnan Sells 1,529 Shares

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 1,529 shares of the firm's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $229,350.00. Following the sale, the insider owned 1,438,711 shares of the company's stock, valued at $215,806,650. This represents a 0.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Suma Krishnan also recently made the following trade(s):

• On Wednesday, July 16th, Suma Krishnan sold 1,389 shares of Krystal Biotech stock. The stock was sold at an average price of $150.00, for a total value of $208,350.00.
• On Tuesday, July 15th, Suma Krishnan sold 3,084 shares of Krystal Biotech stock. The stock was sold at an average price of $151.01, for a total value of $465,714.84.
• On Tuesday, July 15th, Suma Krishnan sold 3,036 shares of Krystal Biotech stock. The stock was sold at an average price of $150.98, for a total transaction of $458,375.28.
• On Monday, July 14th, Suma Krishnan sold 13,400 shares of Krystal Biotech stock. The shares were sold at an average price of $150.30, for a total transaction of $2,014,020.00.
• On Monday, July 14th, Suma Krishnan sold 13,435 shares of Krystal Biotech stock. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50.
• On Thursday, July 10th, Suma Krishnan sold 6,927 shares of Krystal Biotech stock. The shares were sold at an average price of $150.27, for a total value of $1,040,920.29.
• On Thursday, July 10th, Suma Krishnan sold 6,800 shares of Krystal Biotech stock. The stock was sold at an average price of $150.28, for a total value of $1,021,904.00.
• On Wednesday, July 9th, Suma Krishnan sold 200 shares of Krystal Biotech stock. The shares were sold at an average price of $150.14, for a total value of $30,028.00.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded up $2.35 on Wednesday, hitting $150.08. 280,630 shares of the company's stock were exchanged, compared to its average volume of 287,303. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $219.34. The company has a market capitalization of $4.34 billion, a PE ratio of 36.08 and a beta of 0.67. The firm's 50-day moving average is $135.75 and its 200 day moving average is $156.11.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). The business had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. On average, analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on KRYS shares. Citigroup restated a "neutral" rating and set a $176.00 target price (up from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. Guggenheim cut their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Chardan Capital restated a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Tuesday, June 24th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and an average price target of $213.75.

Institutional Trading of Krystal Biotech

Several institutional investors have recently modified their holdings of the stock. Brooklyn Investment Group raised its stake in Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after acquiring an additional 105 shares in the last quarter. Twin Tree Management LP acquired a new stake in shares of Krystal Biotech during the first quarter worth about $29,000. Fifth Third Bancorp lifted its holdings in shares of Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after purchasing an additional 105 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Krystal Biotech by 128.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock valued at $58,000 after purchasing an additional 177 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in Krystal Biotech during the first quarter worth approximately $74,000. Hedge funds and other institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.